
    
      1. Investigate the tolerance of Chlorogenic acid for injection in human body, determine the
           Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity (DLT) of Chlorogenic acid for
           injection in the advanced malignant tumor subjects;

        2. Determine the human pharmacokinetics characteristic of Chlorogenic acid for injection;

        3. Preliminary observation the effectiveness and effective dose;

        4. Provide the basis for the dosage regimen of phase II/III.
    
  